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Introduction
The Syringae Folium (SF) has been traditionally used for heat clearing and detoxifying, and also, has been utilized to treat bacterial infectious diseases, such as acute enteritis [1] , bacillary dysentery and upper respiratory tract infection in China [2] . Various preparations of SF extracts have been widely applied in current clinical applications. For example, eye drops are able to cure 93% patients suffering from herpes simplex keratitis [3] , tablets display a higher recovery rate for children's acute infections than other antibiotics among 400 clinical cases [4] and SF demonstrates a broad-spectrum natural antibacterial activity in 50 pharyngitis cases [5] . Yan Li Xiao (YLX), with the meaning of "quick-acting anti-inflammation" in Chinese, is one of commercial medicines which consists of water extraction and powder of SF. One of its disadvantage lies in large amounts of tablets (9 to 12 per day) used for patients [6] , due to their
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crude extracts. In order to reduce the pill burden and improve the efficacy, the new extraction technology is necessary under the bioassay-guiding fractionation.
Phytochemical studies demonstrated that iridoid glycosides (IGs) are the main active constituent of SF [7] . IGs are one of the most important natural compounds that are widely distributed in various plant families, which are extensively present in almost all Syringa species and have antimicrobial, antihypertensive, anti-inflammatory, anti-oxidant, and antitumor activities [8] .
Syringa iridoids are generally substituted by various acid fragments and phenolic moieties such as 3, 4-dihydroxy-phenethyl, or caffeic acid, which contribute to their low polarity [8] , and the structural similarity of which are very high.
Methicillin-resistant Staphylococcus aureus (MRSA), which is resulted from the selective pressure of antibiotics currently used, has increased relentlessly and is well recognized as a global nosocomial problem in recent years, especially in patients of intensive care units (ICU) admission and of those who are elderly and repeatedly hospitalized. It has now been the predominant and serious pathogenic bacterium, leading to high morbidity and mortality. [9] [10] [11] [12] . Therefore, the development of anti-MRSA agents with novel mechanisms of action is highly necessary [13] .
To solve above stated issues, an antibacterial effective fraction of SF (ESF) was successfully screened out by using the in vivo and in vitro Methicillin-sensitive Staphylococcus aureus (MSSA) experiments in our previous work [14] . Our current interests lie in that whether the ESF can also
show the anti-MRSA activity due to anti-drug-resistant bacterial activity of SF reported in clinics [15] . In order to investigate the anti-MRSA activities of the ESF and its resulting bioactivity constituents, the in vitro and in vivo antibacterial activity of the fraction, isolated compounds and metabolites of Syringopicroside (Sy, the typical IG of SF) on MRSA have been reported in our present paper.
Experimental

Chemicals and material
SF was identified by Jun Yin, the professor of Shenyang Pharmaceutical University and deposited in the laboratory of the Department of Pharmacognosy. YLX capsules and the
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Vancomycin hydrochloride (VH) were produced by Xiuzheng Pharmaceutical Group (Tonghua, China) and Eli Lilly (Seishin Laboratories, Japan), respectively. All solvents used for the preparation were of analytical grade (Tianjin Bodi Chemical Ind., Co., Ltd, Tianjin, China). Silica gel (100-200 mesh and 200-300 mesh; Qingdao Marine chemical Co., Ltd) was provided by
Yuwang chemicals Industries, Ltd. Acetonitrile, methanol (HPLC-grade) and formic acid were purchased from Fisher Chemicals (USA) and ultra-pure water (18.2 M) was prepared with a Mili-Q water purification system (Milipore, France). The NMR spectra were recorded using 300, 400 and 600 MHz Bruker TOPSPIN 2.1 spectrometer. Chemical shifts are expressed in δ (ppm) with reference to the tetramethylsilane (TMS) peak. Column chromatography (C.C.) was carried out on Sephadex LH-20, silica gel 200-300 mesh.
Preparation of ESF.
SF (1800 g) was prepared and soaked in 75% ethanol (m: v=1: 10) for 30 min, followed by being refluxed for 2 times, 1 hour for each time and then filtered. The filtrate was combined and evaporated in 80 °C to a density of 1.01-1.10 g/ml. The residue was precipitated with water 5 times amount of the residue for 30 min and then centrifuged for 30 min (3000 r/min). The supernatant was evaporated to a density of 1.01-1.10 g/ml (667 g/L for crude drug) and then the concentrated solution was prepared. After that, it was loaded on macroporous resin D101 (2000 g) with the speed of 1 BV/h and adsorbed for 1 h. The ratio of dry weight of the solution and macroporous resin was 1:10, the ratio of diameter and height of the resin column was 1:8.
Solution was eluted by 6 BV of 25 % ethanol and then 8 BV of 55 % ethanol under vacuum of 0.07 MPa. Finally, the 55 % ethanol eluate was collected and concentrated to extract on 80 °C water bath and then evaporate to dryness in vacuum to get the ESF (120.6 g).
Fractionation and isolation.
The ESF (100 g) was further separated by C.C. over a silica gel (1500 g, 10*60 cm) eluted The standard stock solution of the separated compounds were prepared and diluted with methanol to appropriate concentrations. Dried powder (2 mg) of ESF was accurately weighed and diluted with methanol to 0.2 mg/ml. The resultant solution was filtered through a 0.22-μm filter for UPLC-TOF-MS analysis.
UPLC-QTOF-MS qualitative analysis of the active fraction
Isolation and purification of the metabolites of Sy from the urine samples
Twenty male SD rats weighing 200-220 g were used. All of the experimental animals were purchased from the Pharmacology Experimental Center of Shenyang Pharmaceutical University.
All of the mice and rats were acclimatized for one week in a light-and temperature-controlled The urine sample was firstly extracted with 3 L of EtOAc for four times and then extracted with 2 L of n-butyl alcohol for four times. The extractions were evaporated to dryness under 50 °C. The
EtOAc extraction (2.1 g) was applied to Sephadex LH-20 C.C. for 7 times using a MeOH system and separated into three fractions: UE1 (163 mg), UE2 (302 mg) and UE3 (233 mg) . The n-butyl alcohol extraction was applied onto the silica gel C.C using a CH 2 Cl 2 -MeOH (4:1~1:1, v/v) system and was separated into three fractions: UE4 (748 mg), UE5 (168 mg) and UE6 (522 mg). MA1 (7 mg) and MA2 (6 mg) was obtained from UE2 by repeated silica gel C.C (15 g, 2*30 cm), eluted using P. 
2.6
In vitro Antibacterial assays
Bacterial stains and culture conditions
The test organisms used in this study were as follows: S. aureus ATCC 6538 (MSSA) and clinical isolated MRSA were obtained from the Chinese People's Liberation Army 463 hospital.
The stains were used to the test minimum inhibitory concentrations (MICs) and were cultured overnight in nutrient broth at 37 °C and stored at 4 °C.
Broth micro dilution assay for determination of the MIC
The MIC values for the microorganisms were determined as sensitivity to compounds in microdilution assay [10] . Briefly, the 96-well plates were prepared by dispensing 120-μ1 broth and 30-μ1 inoculum into each well. A 150-μ1 extract initially prepared at the concentration of 4 or 5 mg/ml was added into the first well. Then, 150-μ1 from their serial dilutions was transferred into eight consecutive wells. The final volume in each well was 150μ1. Equal volumes of each bacterial strain culture, which contained approximately 10 6 CFU/ml, were applied to sterile NB supplemented with multiple proportion dilutions of the samples at concentrations ranging from 0.03125 mg·ml -1 to 2 mg·ml -1 in 96-well plates. These serially diluted cultures were then incubated at 37 °C for 18 h. The MIC was defined as the lowest concentration of the compound to inhibit the growth of microorganisms.
In vivo antibacterial experiment
The mice were randomly divided into nine groups with 8 mice in each group. The mice in the ESF groups received the ESF fraction, according to the formula recorded in the pharmacology experimental methodology edited by Chen [7] . The oral administration dose of the low-dose group
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was calculated by coefficient commutation of somatotypes based on the clinical dose of SF [11] 
Results
Phytochemical investigation of ESF by column chromatograph and UPLC-TOF-MS analysis
From the ESF, 6 iridoid glucosides, including Syringopicroside (1), Syringopicroside B (2), Syringalactone B (3), Ligustroside (4), Griffithoside B (5) and Formoside (6) were obtained. The structures (Fig.1a) were elucidated on the basis of 1 H, 13 C-NMR and MS data and by comparison with the references [16] [17] [18] [19] . The NMR data of these compounds was provided in supplement data.
The UPLC-TOF-MS analysis showed the presence of the isolated compounds in the ESF. The compounds were identified in comparison of their retention time and MS spectra with external standards. Sy, the maximum amount of compound, together with other 5 IGs were identified as the major components of ESF (Fig.1b) .
The isolation and elucidation of in vivo metabolites of Sy
A total of seven metabolites (MA1-MA7) were isolated from the urine of rats after oral administrated with Sy. To our best knowledge, all isolated compounds were identified as the in vivo 
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by comparison with those existing NMR data in references [19, [22] [23] [24] [25] (Fig.2) .
The in vitro antibacterial activity of ESF, Sy and its analogues (IGs) from ESF
The in vitro anti-MSSA and anti-MRSA activity of the ESF and YLX were evaluated and compared ( Table 1 ). The dosage of each fraction was decided based on the previous anti-MSSA study [14] . Against the two test organisms, the MIC values of YLX were 2.45 and 4.90 mg·ml -1 , respectively, which were twice or even quadruple higher than that of ESF (1.28 and 1.28 mg·ml -1 ).
It means the antibacterial constituents of YLX have been effectively enriched by ESF, and thus we assume anti-MSSA activity of ESF could be sensitive to MRSA.
In order to determine the antibacterial materials basis of the ESF and figure out whether the IGs are the active ingredients, the isolated IGs were first evaluated using the MIC values (Fig.3 ).
Generally speaking, the susceptibility of the tested samples to MRSA is lower than which to MSSA. 
The in vitro antibacterial activity of Sy metabolites of against MRSA and MSSA
In order to determine whether the in vivo metabolites of Sy are the real bioactive constituents and whether Sy plays the important role in anti-MRSA bacteria activity of ESF, the in vitro anti-MRSA and anti-MSSA activities of the isolated metabolites of Sy were tested and compared (Fig.4) . Among the isolated metabolites, the MA1 and MA2 performed a lower MICs comparing with their original compound 1 (Sy), which indicated that the hydrolyzed aglycone possessed better antibacterial activities. Especially, the MA5 and MA6 performed very low MICs both in the MSSA and MRSA testing, both of which may be the final metabolites of Sy. But another three metabolites, MA3, MA4 and MA7, did not have the antibacterial activity against MRSA, and meanwhile MA3 and MA4 possessed strong activity against MSSA.
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The in vivo antibacterial activity of ESF and Sy.
The in vivo antibacterial activity of the ESF was characterized by survival rates in the experimental peritonitis model. Three ESF groups which received different dosage were used as therapeutic plan, while YLX and VH were tested as two positive control groups. The survival rates of the blank control group and the VH group were 42.8% and 100%, respectively, which demonstrates that the experimental models were successfully established. In the therapeutic plan, the oral administration dose of the low-dose group was calculated by coefficient commutation of somatotypes based on the clinical dose of SF [6] as 82. Sy is typical IGs from SF and accounts for over 30% of ESF, reported in our previous paper [20] . To determine whether Sy is the anti-MRSA active component of ESF, the in vivo antibacterial activity of the Sy was characterized as a breakthrough point by the survival rates in the experimental peritonitis model. In the Fig.6 , the survival rate of the model group (K) gradually reduced as time goes on, and finally fell straight to the 42.8%; while the survival rate of the positive control group (ESF-M) remained at 100%. In the therapeutic groups, orally administered Sy (27.4, 54.8, 109.6 mg/kg) performed different protective effects: Sy-H group kept zero death to the 4 th day
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Seven metabolites of Sy from the urine of rats are reported, and then the in vitro antibacterial activity of these isolated metabolites were evaluated and compared with those of the parent compound (Sy). The hydrolyzed product (MA1) and the derivative (MA2) performed lower MICs than that of Sy, which demonstrates that MA1 and MA2 have better antibacterial activities. Smaller molecules of aglycone support a better membrane permeability of the bacteria, which could be speculated to be the in vivo material basis of the bioactivity.
Our previous study [14] showed that the antimicrobial fraction of SF exhibits a more long-lasting activity than the clinical used antibiotic, which might be induced by a multiple components effects. LIU et al. found that Sy are rapid distribution, fast elimination and the retention time was very short [29] . Based on these facts, the metabolites are the main existing form instead of the mother compound. Considered the similarity and diversity of the IGs in structure (Fig.1a) , the deglycosylation may widely exist but the reaction rates differed from each other under the action of different hydrolytic enzymes. It is supported that the actual compounds responsible for the antibacterial activity were produced in a more gradual way. The greater antibacterial activity of the metabolites of Sy could partly explain this phenomenon.
Conclusion
In current study, the in vivo and in vitro anti-MRSA material basis of the effective fraction of SF was studied by testing the anti-MRSA activity. A total of 6 IGs isolated from ESF and 7 metabolites of a typical IG, Sy, were isolated from rat urine and characterized by NMR and MS. It is the first time that we conduct a comprehensive investigation of the in vivo metabolites of Sy.
The anti-MRSA activity of its metabolites were surveyed and compared with each other. This study conducts preliminary research on the metabolic process of the main constituents of SF and also lays the foundation for the further research and development of Syringae Folium to justify its use in the traditional medicine. VH group (300 mg·kg -1 , n=7) and blank control group (untreated, n=7). 
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